The Price of Survival: Global Inequities in Anti‐GD2 Immunotherapy for Neuroblastoma
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Ruzanna Papyan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Hauptthemen laut MEDLINE: Neuroblastoma, Immunotherapy, Gangliosides, Healthcare Disparities. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Background
Long‐term survival for high‐risk neuroblastoma has increased from 40% to 60% by optimizing chemotherapy, surgery, radiation therapy, and the addition of anti‐GD2 antibody therapy. However, the high cost of this antibody presents access issues globally. This study evaluates the availability, financial coverage, and barriers to accessing these therapies across diverse healthcare settings.
Methods
An online survey collected data on demographics, treatment practices, financial coverage, regulatory status, and barriers to anti‐GD2 therapy. Fisher's exact test was used to compare categorical variables between high‐income countries (HICs) and low‐ and middle‐income countries (LMICs). A retrospective cost analysis estimated the financial burden of anti‐GD2 therapies using standardized dosing for a representative 3‐year‐old patient.
Results
Responses came from 100 facilities in 80 cities and 59 countries. Anti‐GD2 therapy for frontline maintenance was available in 93% of HIC centers, but only 21% of LMIC centers; 65% of LMIC centers reported no access, while the remainder had limited or irregular availability ( p < 0.0001, Fisher's exact test). When unavailable, isotretinoin was most often used alone. Financial coverage differed significantly: HICs relied on government or insurance funding, while LMICs depended on out‐of‐pocket or non‐profit support. Cost analysis showed a full treatment course would cost approximately $192,750 for dinutuximab, $142,695 for dinutuximab beta, and $610,800 for naxitamab, highlighting the substantial financial burden these therapies impose.
Conclusion
Global access to anti‐GD2 therapy is highly unequal. Strategic measures, including negotiations for reduced drug costs, research‐based access, and WHO Essential Medicines List inclusion, could help address these disparities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yeolyan Hematology and Oncology Center, Yerevan, Armenia.
- Department of Pediatric Oncology and Hematology, Yerevan State Medical University, Yerevan, Armenia.
- Immune Oncology Research Institute, Yerevan, Armenia.
- Resonance Inc., Memphis, Tennessee, USA.
- Hospital de Clínicas Jose de San Martin, Buenos Aires, Argentina.
- Nationwide Children's Hospital, Columbus, Ohio, USA.
ORCID-Profile: Ruzanna Papyan, Gabriella Villanueva
Zitieren
APA
Papyan, R., Hoveyan, J., Guscott, M., Lowe, J., Villanueva, G., Streby, K. A., Tadevosyan, E., Demirtshyan, E., Hylton, J., Tamamyan, G., Lam, C. G., Matthay, K., & Howard, S. C. (2026). The Price of Survival: Global Inequities in Anti‐GD2 Immunotherapy for Neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70152
Vancouver
Papyan R, Hoveyan J, Guscott M, Lowe J, Villanueva G, Streby KA, et al. The Price of Survival: Global Inequities in Anti‐GD2 Immunotherapy for Neuroblastoma. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70152
BibTeX
@article{Papyan2026,
author = {Papyan, Ruzanna and Hoveyan, Julieta and Guscott, Martin and Lowe, Jennifer and Villanueva, Gabriella and Streby, Keri A and Tadevosyan, Emma and Demirtshyan, Ester and Hylton, Jennifer and Tamamyan, Gevorg and Lam, Catherine G and Matthay, Katherine and Howard, Scott C},
title = {The Price of Survival: Global Inequities in Anti‐GD2 Immunotherapy for Neuroblastoma},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70152}
}
EUVIMED